Skip to main content

Table 2 Characteristics of patient study groups

From: Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort

  No change of DMARD Change of DMARD Reason for change
Adverse drug reaction Lack of efficacy
N 356 410 139 230
Female 65% 72% * 71% 72%
Age (yrs) 58 (47–68) 56 (46–66) 60 (50–70) 54 (44–63) **
BMI (kg/m2) 26.4 (23.9 - 30.1) 26.9 (23.7 - 30.8) 26.6 (23.8 - 30.5) 27.2 (23.9 - 31.2)
Ever smoked 57% 65% * 66% 65%
Current smoker 35% 39% 39% 37%
Symptom duration (mo) 6 (4–12) 6 (4–12) 5 (3–10) 6 (3–13)
Erosions 47% 26% 23% 28%
HAQ (0–3) 1.0 (0.4 - 0.6) 1.4 (0.8 - 1.9) ** 1.3 (0.6 - 1.8) * 1.4 (0.8 - 1.9) **
>4 of 1987 ACR criteria 51% 59% * 53% 65% **
Seropositive 62% 61% 54% 64%
Extra-articular disease 11% 20% ** 15% 24% **
Co-morbidity 44% 50% 56% * 49%
DAS28 4.6 (3.6 - 5.7) 5.1 (4.0 - 6.1) ** 4.8 (3.5 - 5.7) 5.4 (4.1 - 6.2) **
DAS28-P (0–1) 0.41 (0.32 - 0.47) 0.43 (0.35 - 0.50) ** 0.42 (0.32 - 0.50) 0.43 (0.37 - 0.50) **
SF36-Bodily pain (0–100) 41 (31–62) 32 (22–51) ** 41 (22–62) * 31 (21–42) **
SF36-Mental Health (0–100) 68 (52–80) 60 (48–72) ** 60 (48–72) ** 56 (48–70) **
Steroid at baseline 17% 16% 14% 16%
Sulphasalazine monotherapy 27% 43% 59% 33%
Methotrexate monotherapy 53% 36% 23% 48%
Other monotherapy 4% 11% 9% 12%
Dual therapy 6% 5% 7% 4%
Triple therapy 10% 4% 2% 4%
  1. Comparison of patient groups based upon DMARD changes. Medians (IQR) or percentage prevalences are presented. ** p < 0.01, * p < 0.05 for comparison vs No Change. Statistically significant results are presented in bold (with the exception of DMARD treatments, which were also significantly heterogeneous, but tested as a group).